Active substance
Results for the substance sebelipase alfa
1 result
About this active substance
Sebelipase alfa is a recombinant enzyme used in the treatment of lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder characterized by lipid accumulation in various organs. This enzyme replaces the deficient or absent lysosomal acid lipase, facilitating the breakdown of cholesterol esters and triglycerides within lysosomes.
Sebelipase alfa is administered via intravenous infusion, typically once weekly or biweekly, depending on the severity of the disease. It is used to reduce lipid accumulation, improve liver function, and prevent severe complications such as liver failure or early-onset atherosclerosis.
Common side effects include infusion site reactions, fever, headache, and fatigue. In rare cases, severe allergic reactions or anaphylaxis may occur. Careful monitoring during administration is essential to ensure patient safety.
Sebelipase alfa represents an innovative therapy for patients with LAL-D, providing an effective option for managing this rare and severe condition.
Sebelipase alfa is administered via intravenous infusion, typically once weekly or biweekly, depending on the severity of the disease. It is used to reduce lipid accumulation, improve liver function, and prevent severe complications such as liver failure or early-onset atherosclerosis.
Common side effects include infusion site reactions, fever, headache, and fatigue. In rare cases, severe allergic reactions or anaphylaxis may occur. Careful monitoring during administration is essential to ensure patient safety.
Sebelipase alfa represents an innovative therapy for patients with LAL-D, providing an effective option for managing this rare and severe condition.